top of page

Multiple Sclerosis (MS)

Statistics on Multiple Sclerosis:

Multiple sclerosis affects about 400,000 people in the United States, and about 2 ½ million worldwide.

“Autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age.”

“Commonly used immunosuppressant treatments lead to devastating long-term side effects.”

(Source: American Autoimmune Related Diseases Association, Inc. (AARDA), /news-information/statistics)

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

Zajicek, J. P., et al.

Journal of Neurology, Neurosurgery & Psychiatry. 2005, 76: 1664-1669 (Full).

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

Svendsen, Kristina B., et al.

BMJ. 2004 May 12, 329 (online paper).

Cannabis for Multiple Sclerosis

Fox, P.J., et al.

Practical Neurology. 2002, 2(3): 154-160 (Full).

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

Iskedjian, Michael, et al. 

Current Medical Research and Opinion. 2007, 23(1): 17-24 (abstract). 

Randomized, controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

Collin, C., et al.

European Journal of Neurology. 2007 Mar, 14(3): 290-296 (abstract).

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

Rog, David J., et al.

Neurology. 2005 Sep 27, 65(6): 812-819 (abstract).

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients  

Wade, Derick T., et al.

Multiple Sclerosis Journal. 2004, 10(4): 434-441 (abstract).      

Cannabinoids in Multiple Sclerosis

Killestein, Dr. Joep, et al.

Drugs. 2004 Jan, 64(1): 1-11 (abstract). 

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial 

Zaicek, J. P., et al.

The Lancet. 2003 Nov 8, 362(9395): 1517-1526 (abstract).

Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis

Killestein, J., et al.

Journal of Neuroimmunology. 2003 Apr, 137(1-2): 140-143 (abstract).

The therapeutic potential of cannabis in multiple sclerosis

Baker, David, et al.

Department of Neuroinflammation, Institute of Neurology. 2003 Apr, 12(4): 561-567 (abstract).  

Cannabinoids and multiple sclerosis

Pertwee, Robert G.

Pharmacology & Therapeutics. 2002 Aug, 95(2): 165-174 (abstract).


Cannabinoids control spasticity and tremor in a multiple sclerosis model

Baker, David, et al.

Nature. 2000 Mar 2, 404: 84-87 (abstract).

The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis

Consroe, P., et al.

European Neurology. 1997, 38(1): 44-48 (abstract).   

Multiple Sclerosis: About Us
bottom of page